Intravesical BCG Treatment for Bladder Cancer in Kuala Lumpur
Bladder-preserving treatment for selected patients with non-muscle-invasive bladder cancer
Intravesical BCG Treatment for Bladder Cancer in Kuala Lumpur
Bladder-preserving treatment for selected patients with non-muscle-invasive bladder cancer
Bladder cancer does not always require removal of the bladder. When cancer is confined to the inner lining of the bladder, treatment may involve removing the tumour through a procedure called transurethral resection of bladder tumour (TURBT), followed by additional treatment to reduce the risk of recurrence or progression.
One established treatment is intravesical Bacillus Calmette-Guérin (BCG) therapy, in which a solution containing weakened BCG bacteria is introduced directly into the bladder.
BCG stimulates an immune response within the bladder, helping the body recognise and attack remaining cancer cells. It is commonly recommended for patients with certain intermediate-risk and high-risk forms of non-muscle-invasive bladder cancer.
What Is Intravesical BCG Therapy?
BCG was originally developed as a vaccine against tuberculosis. In bladder cancer treatment, it is used differently: rather than being injected into the bloodstream or muscle, BCG is delivered directly into the bladder through a thin urinary catheter.
The treatment activates local immune responses against bladder cancer cells.
Unlike chemotherapy, which directly damages cancer cells, BCG works primarily by stimulating the body’s immune system.
Intravesical BCG is used after the visible tumour has been removed. Its purpose is to treat microscopic cancer cells that may remain in the bladder and reduce the likelihood of the cancer returning or progressing.
Who May Benefit From BCG Treatment?
Not every patient with bladder cancer requires BCG.
Treatment recommendations depend on the tumour’s grade, stage, size, number of tumours, previous recurrence history, and other pathological findings.
BCG is commonly considered for:
High-grade Ta bladder cancer: Cancer confined to the inner lining of the bladder, with features associated with a higher risk of recurrence or progression.
T1 bladder cancer: Cancer that has grown into the connective tissue beneath the bladder lining but has not invaded the bladder muscle.
Carcinoma in situ (CIS): A flat, high-grade cancer affecting the bladder lining that may not form a visible tumour.
Selected intermediate-risk bladder cancers: Particularly where the risk of recurrence warrants additional treatment.
For low-risk bladder tumours, BCG is generally unnecessary. Other treatments or surveillance may be more appropriate.
For muscle-invasive bladder cancer, BCG alone is not an adequate treatment.
Why Is BCG Recommended After TURBT?
TURBT removes visible bladder tumours, but it does not eliminate the possibility of cancer returning.
Bladder cancer has a recognised tendency to recur, even when the initial tumour has been completely removed.
BCG is used to reduce this risk, particularly in patients whose tumour characteristics suggest a greater likelihood of recurrence or progression.
For selected high-risk patients, BCG may help preserve the bladder while maintaining cancer control.
However, BCG does not guarantee that cancer will not return. Regular cystoscopic surveillance remains essential throughout and after treatment.
How Is Intravesical BCG Administered?
BCG treatment is usually performed as an outpatient procedure and does not generally require anaesthesia.
Before treatment
The clinical team checks for symptoms of urinary infection, significant bleeding, or other reasons to postpone treatment. BCG is usually started at least two weeks after TURBT, once the bladder has healed sufficiently.
Insertion of a urinary catheter
A thin catheter is passed through the urethra into the bladder. The BCG solution is then introduced through the catheter.
Holding the medication in the bladder
The catheter is usually removed after administration. Patients are generally asked to retain the solution for approximately two hours, if tolerated, to allow contact with the bladder lining.
Emptying the bladder
After the recommended retention period, the patient urinates to empty the bladder. Specific hygiene precautions are required because the urine may contain live BCG organisms.
Returning home
Most patients can return home after treatment. The clinical team provides instructions regarding fluid intake, toilet hygiene, expected symptoms, and when to seek medical attention.
Patients should follow the treatment centre’s specific instructions, including precautions when using the toilet during the first six hours after treatment.
How Many BCG Treatments Are Needed?
BCG treatment is usually delivered in two phases.
Initial Treatment (Induction)
The standard induction course consists of one treatment per week for six weeks.
This initial course aims to stimulate an immune response against remaining bladder cancer cells.
Maintenance Treatment
Depending on the patient’s risk category, response, tolerability, and BCG availability, further treatments may be recommended.
A commonly used maintenance schedule involves three weekly treatments at specified intervals following induction.
For high-risk bladder cancer, maintenance therapy may continue for one to three years, when appropriate and tolerated. Intermediate-risk patients may require a shorter course.
The treatment schedule is determined by the patient’s cancer risk and clinical circumstances rather than following the same regimen for everyone.
How Effective Is BCG for Bladder Cancer?
Intravesical BCG is an established treatment for reducing the risk of recurrence and progression in selected patients with non-muscle-invasive bladder cancer.
Clinical studies have demonstrated measurable benefits:
Cancer recurrence: In studies comparing BCG after tumour removal with surgery alone, approximately 29% of patients receiving BCG experienced recurrence within 12 months, compared with 56% without BCG.
Cancer progression: A meta-analysis involving 4,863 patients found progression rates of 9.8% with BCG compared with 13.8% in control groups over a median follow-up of 2.5 years. The reduction was demonstrated in patients receiving maintenance BCG.
These results come from different studies and comparison groups. The progression analysis included controls receiving treatments other than BCG, rather than surgery alone exclusively.
Treatment outcomes depend on tumour stage, grade, previous recurrence history, and completion of the recommended treatment schedule.
Although BCG can provide sustained disease control, some bladder cancers may persist or recur despite treatment. Regular cystoscopic surveillance remains necessary to assess treatment response and detect recurrence.
What Are the Side Effects of Intravesical BCG?
Because BCG stimulates an immune response in the bladder, temporary urinary symptoms are common.
These may include:
Increased urinary frequency and urgency
Burning or discomfort during urination
Mild blood in the urine
Bladder discomfort or pelvic pain
Fatigue, mild fever, or flu-like symptoms
These symptoms often develop within the first 24–48 hours and usually improve without specific treatment.
When Should Patients Seek Medical Attention?
Although uncommon, BCG can occasionally cause a serious infection or systemic inflammatory reaction.
Patients should seek urgent medical assessment if they develop persistent or high fever, shaking chills, severe weakness, breathlessness, or worsening general condition after treatment.
A fever of 38.5°C or above lasting more than 48 hours, or a fever above 39.5°C lasting at least 12 hours, requires urgent assessment. Patients who are acutely unwell should not wait for these thresholds.
Severe reactions may require hospital treatment and medication directed against BCG infection.
When Should BCG Treatment Be Delayed or Avoided?
BCG should not be administered in certain circumstances because of the risk of complications.
These include active symptomatic urinary tract infection, visible blood in the urine, recent traumatic catheterisation, or insufficient healing after bladder surgery.
BCG is also generally avoided in patients with significant immunosuppression, and it is contraindicated during pregnancy.
Before each treatment, the clinical team assesses whether it is safe to proceed.
Is Follow-Up Still Necessary After BCG?
Yes. BCG reduces the risk of bladder cancer recurrence but does not eliminate it.
Regular surveillance is an essential part of treatment.
Follow-up commonly includes cystoscopy to examine the bladder lining, with urine cytology and imaging when indicated.
The first surveillance cystoscopy is generally performed around three months after TURBT. Subsequent examinations depend on the original tumour’s risk category and findings during follow-up.
Patients with high-risk non-muscle-invasive bladder cancer usually require long-term surveillance, even after completing BCG treatment.
Early identification of recurrence allows further treatment to be considered before the disease progresses.
What Happens if BCG Treatment Does Not Work?
Some bladder cancers persist or recur despite BCG treatment.
The next step depends on the timing of recurrence, tumour grade and stage, previous BCG exposure, and the patient’s overall health.
In selected cases, further intravesical treatment or other bladder-preserving approaches may be considered.
However, for patients with BCG-unresponsive high-risk disease, early radical cystectomy is often the recommended treatment, particularly when delaying surgery could increase the risk of progression.
The decision requires careful discussion of cancer control, treatment risks, and the patient’s preferences.
Intravesical BCG Treatment in Kuala Lumpur
Management of non-muscle-invasive bladder cancer involves more than removing the initial tumour.
Appropriate treatment requires an assessment of the tumour’s pathological features, recurrence risk, and the need for additional therapy.
Dr Roger Anthony Idi, Consultant Urologist at Prince Court Medical Centre, Kuala Lumpur, provides assessment and management of bladder cancer, including evaluation following TURBT, consideration of intravesical treatment, and ongoing cystoscopic surveillance.
Treatment recommendations are based on the tumour’s risk classification, previous treatment, and the patient’s clinical circumstances.
Patients who have been advised to undergo BCG treatment, or whose bladder cancer has recurred after previous treatment, may arrange a consultation to discuss the available management options.
For bladder cancer assessment and treatment planning, appointments can be arranged with Dr Roger Anthony Idi at Prince Court Medical Centre, Kuala Lumpur.
Frequently Asked Questions
Is BCG treatment the same as chemotherapy?
No. BCG is a form of intravesical immunotherapy that stimulates the immune system within the bladder. Intravesical chemotherapy uses medications that act directly against cancer cells.
Is BCG treatment painful?
Most patients experience some discomfort during catheter insertion, but the procedure is generally well tolerated. Burning, urgency, or bladder irritation may occur after treatment.
Can BCG cure bladder cancer?
BCG can produce a complete response in some patients, particularly those with carcinoma in situ, and reduce the risk of recurrence or progression. However, it does not guarantee a permanent cure, and ongoing surveillance is necessary.
Can bladder cancer return or progress after BCG treatment?
Yes. Although BCG significantly reduces the risk of bladder cancer returning or progressing, it does not eliminate these risks.
Clinical studies have demonstrated:
Recurrence: At 12 months, bladder cancer returned in approximately 29% of patients receiving BCG after tumour removal, compared with 56% of patients treated with surgery alone.
Progression: A large analysis involving 4,863 patients found that 9.8% of those receiving BCG experienced progression to muscle-invasive disease, compared with 13.8% in control groups, over a median follow-up of 2.5 years. The reduction was demonstrated in patients receiving maintenance BCG.
These findings support the role of BCG in reducing recurrence and delaying or preventing progression in selected patients with non-muscle-invasive bladder cancer.
However, treatment outcomes vary according to tumour stage, grade, risk category and response to BCG. Regular cystoscopic surveillance remains essential, even after completing treatment.
Will I need to stay in hospital for BCG treatment?
BCG is generally administered as an outpatient procedure. Hospital admission is not routinely required unless complications occur.
Can I continue working during BCG treatment?
Many patients continue their usual activities, although urinary symptoms or fatigue may temporarily affect their routine. Adjustments may be necessary depending on how they respond to treatment.
Can BCG treatment be repeated if bladder cancer returns?
Sometimes. The decision depends on the type of recurrence, how much BCG was previously received, and how soon the cancer returned. Further BCG is generally not recommended for BCG-unresponsive high-risk disease.
Related Reading
- Bladder Cancer: Symptoms, Diagnosis and Treatment – Understand how bladder cancer is diagnosed, staged and managed.
- TURBT: Transurethral Resection of Bladder Tumour – Learn how TURBT is performed to remove visible bladder tumours, obtain tissue for diagnosis and staging, and guide further treatment.
- Blood in Urine (Haematuria): Causes and Assessment – Learn why visible or microscopic blood in the urine requires investigation.
- Frequent Urination: Causes and When to Seek Assessment – Understand urinary symptoms that may arise from bladder conditions.
- Difficulty Passing Urine and Urinary Retention – Learn about possible causes of difficulty emptying the bladder and available treatment options.